What is the story about?
What's Happening?
Aphios Corporation has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Center for Complementary & Integrative Health (NCCIH) of the National Institutes of Health (NIH). This grant will support the development of Zindol, a botanical drug derived from ginger, aimed at treating chemotherapy-induced nausea and vomiting (CINV). Previous clinical studies have shown Zindol's effectiveness in reducing nausea significantly compared to Zofran, without adverse side effects. The grant will enable Aphios to develop a next-generation formulation of Zindol with higher purity and evaluate its activity in innovative assays.
Why It's Important?
Chemotherapy-induced nausea and vomiting (CINV) is a common and distressing side effect affecting up to 70% of adult cancer patients. Current treatments often lead to debilitating side effects, causing some patients to refuse further chemotherapy, which can be life-threatening. Zindol offers a potentially safer and more effective alternative, which could improve the quality of life for millions of cancer patients. The development of Zindol could also reduce the need for synthetic antiemetics, lowering treatment costs and expanding therapeutic options in the $3.4 billion antiemetics market.
What's Next?
Aphios plans to pursue Phase II IND-enabling toxicology studies and future Phase III clinical trials. The goal is to license Zindol to a strategic pharmaceutical partner, addressing the growing demand for effective antiemetic solutions. If successful, Zindol could become a key player in the antiemetics market, providing a natural and effective treatment option for cancer and obesity patients worldwide.
AI Generated Content
Do you find this article useful?
